First in Human (FIH) to Proof of Concept (POC)

Accelerating molecules to POC.

FIH to POC. Fast.

Translational Pharmaceutics®: For FIH programs

Reduces time

to achieve POC milestone

Minimizes costs

in upfront chemistry, manufacturing, and controls (CMC)

Increases precision

and flexibility in your study

Formulation optimization

based on emerging clinical data

Customizes drug product

supply to the needs of your study

Simplifies supply

and streamlines delivery

Accelerating FIH to POC: What our customers say

R552 is a potent and selective RIP1 kinase inhibitor that blocks inflammatory cell death downstream of death receptors. It is being developed at Rigel Pharmaceuticals for treatment of autoimmune and inflammatory disorders. We were very delighted to have Quotient Sciences on board and they worked with us on the formulation development as well as the first-in-human study of R552.

Dr. Lucy Yan

VP, Clinical Development , Rigel Therapeutics

Expert insight for FIH programs

More Blogs

Translational Pharmaceutics, First-in-Human Integrated Development Strategies - Part 1: Leveraging clinical data to accelerate from first-in-human (FIH) to proof of concept (POC) By: John McDermott

Candidate Development, First-in-Human How to streamline the development of your molecule from candidate selection to first-in-human clinical testing By: Stephen Byard

Formulation Development, Healthy Volunteer Trials, First-in-Human, Human ADME Balancing time, cost and development risk when choosing the appropriate dosage form for your first-in-human Phase I trials By: Dr. Peter Scholes

More Blogs

Humanity can't afford to wait, so neither can we.

Let's talk